Two rotavirus vaccines, Rotarix (RV1) and RotaTeq (RV5), were licensed for global use in 2006. A systematic review of 48 peerreviewed articles with postlicensure data from 24 countries showed a median RV1 vaccine effectiveness (VE) of 84%, 75%, and 57% in countries with low, medium, and high child mortality, respectively, and RV5 VE of 90% and 45% in countries with low and high child mortality, respectively. A partial vaccine series provided considerable protection, but not to the same level as a full series. VE tended to decline in the second year of life, particularly in medium-and high-mortality settings, and tended to be greater against more severe rotavirus disease. Postlicensure data from countries across geographic regions and with different child mortality levels demonstrate that under routine use, both RV1 and RV5 are effective against rotavirus disease, supporting the World Health Organization recommendation that all countries introduce rotavirus vaccine into their national immunization program.
Before the availability of vaccines against rotavirus, this pathogen was the leading cause of severe gastroenteritis in children <5 years of age worldwide [1] . Since 2006, 2 oral live attenuated rotavirus vaccines have been licensed for use globally: Rotarix (GlaxoSmithKline, Rixensart, Belgium, hereafter referred to RV1), a monovalent vaccine based on a single human rotavirus strain, and RotaTeq (Merck and Co, Westpoint, Pennsylvania, hereafter referred to as RV5), a pentavalent vaccine based on 5 bovine-human reassortant rotavirus strains. As of 2 December 2016, 82 countries have added rotavirus vaccines to their national immunization programs ( Figure 1 ); an additional 6 countries have introduced rotavirus vaccines subnationally [2] [3] [4] . Furthermore, in many other countries, rotavirus vaccines are available for private market use.
After clinical trials showed high efficacy (85%-98%) of both vaccines in high-income and upper-middle-income countries in the Americas, Asia, and Europe, many countries in these regions were the first to implement national rotavirus vaccination programs beginning with the United States in early 2006 [5, 6] . Subsequent clinical trials conducted in low-income countries in Africa and Asia showed modest efficacy (50%-64%) but a substantial absolute public health impact of vaccination given the very high rotavirus disease burden in these countries [7] [8] [9] . Based on these data and early vaccination impact data from the Americas, in 2009 the World Health Organization (WHO) issued a recommendation for the inclusion of rotavirus vaccines in all national immunization programs, especially in countries with high gastroenteritis-associated mortality [10] .
Previous reviews of rotavirus vaccine effectiveness (VE) have focused on data generated within the first few years of global licensure, when use of rotavirus vaccines was largely limited to high-and middle-income countries of the Americas and Europe [11] [12] [13] [14] [15] [16] . Since 2012, many low-and middle-income countries in Africa have implemented routine rotavirus vaccination, and initial evaluations of rotavirus VE from several of these countries have recently been published [17] [18] [19] [20] . We analyzed up to 10 years of postlicensure data from countries across geographic regions and across child mortality strata to assess the effectiveness of rotavirus vaccines in routine programmatic use. Furthermore, we examined issues that were not fully addressed in prelicensure trials, including the effectiveness of incomplete vaccination series, protection beyond the first year of life, and effectiveness by disease severity.
METHODS

Search Strategy and Selection Criteria
Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [21] , we identified articles published between 1 January 2006 and 2 December 2016 by searching for the terms "rotavirus" and either "vaccin*" or "immuni*" in the PubMed, Medline, Embase, and Global Health databases. The selection criteria and process is outlined in Figure 2 . We included postlicensure, observational evaluations of full-series RV1 or RV5 VE. We excluded studies if they were not relevant to our question, such as those addressing safety, disease burden, parent or healthcare provider knowledge attitudes and practices, laboratory methods, and economic impact, or were not observational evaluations, such as randomized controlled trials, predictive modeling, meta-analyses, and systematic reviews.
Study Selection and Data Abstraction
We developed a standardized data abstraction form, and 2 reviewers independently abstracted information on study setting, study period, age of study population, number of case patients and controls, vaccine type, and VE; discrepancies were reconciled. For the data analyses, we included only those articles that provided information on case patients enrolled from hospitals, emergency departments (ED), or outpatient clinics, and on controls who were rotavirus test-negative diarrhea patients from the same settings as case patients or, when rotavirus test-negative diarrhea controls were unavailable, nondiarrhea controls who were enrolled from the community. We limited the age groups, outcomes of interest, and control groups included to control for bias in summary results. We excluded articles that reported mixed RV1 and RV5 VE, without additional stratification by vaccine type, and that used an alternate VE calculation (ie, through imputed coverage).
Data Analysis
We reviewed overall VE against rotavirus hospitalization, ED visits, and outpatient encounters, stratified by under-5 child mortality of the country where the study was conducted. We assessed for publication bias with funnel plots. All VE estimates represent a complete vaccine series (2 doses of RV1 or 3 doses of RV5) unless otherwise specified. We plotted individual reported VE point estimates by country-specific under-5 child mortality rates [22, 23] and calculated median unweighted VE estimates by mortality strata. We also did a meta-analysis using a random-effects model by vaccine and country under-5 mortality strata; I 2 and Q statistics describing the heterogeneity are also presented. There were not sufficient data to perform a meta-analysis for any of the secondary outcomes. We created mortality strata based on quartiles from 2014 under-5 child mortality rates [22] . We defined low-mortality countries as those in the lowest quartile of under-5 child mortality rates, medium-mortality countries as those in the second quartile, and high-mortality countries as those in the highest 2 quartiles. We also reviewed selected articles for 3 VE subanalyses: effectiveness of incomplete vaccination series, protection beyond the first year of life, and effectiveness by disease severity. We reviewed VE estimates against rotavirus healthcare encounters for 1 dose of RV1 and 1 or 2 doses of RV5 to assess VE of an incomplete rotavirus vaccine series. For this analysis, we excluded articles that only provided results for "at least 1 dose" or "any dose" of vaccine. To examine protection beyond the first year of life, we reviewed articles that provided VE estimates against rotavirus hospitalizations and ED visits separately for children <12 months and ≥12 months of age. For examination of VE by disease severity, we reviewed VE by healthcare visit type (ie, hospitalizations, outpatient visits, and ED visits) and by standardized Vesikari severity scores [5] . For these outcomes, medians are presented, as the data were insufficient for a meta-analysis by strata alone. Qualitatively, we sought to limit bias and heterogeneity between studies by considering the ages of the case and control children, outcomes of interest, and control group.
We used Microsoft Excel 2013 software, R version 2.7 statistical programming language (R Development Core, 2008), and Quantum GIS Geographic Information System version 2.8 (Open Source Geospatial Foundation Project) for these analyses.
RESULTS
Selection and Characteristics of Studies
After excluding duplicates and articles not available in English, we reviewed 1349 publications identified by our search ( Figure 2 ). Of these, 1063 publications were excluded because they were not relevant to our question, not methodologically consistent with a VE evaluation, or provided programmatic guidance alone. We then reviewed abstracts of 288 published articles and excluded those that only presented observational rotavirus vaccine impact on healthcare encounters or mortality, prelicensure efficacy, alternate routine dose scheduling, and genotype-specific VE. Of the remaining 61 articles, 48 from 24 countries in the Americas, Africa, Asia, and Europe met our inclusion criteria; these 48 articles report 31 RV1 VE estimates and 27 RV5 VE estimates ( Figure 2 ). We did not find evidence of publication bias (results not presented).
Full Series VE by Under-5 Child Mortality
Plotting RV1 and RV5 VE against combined rotavirus hospitalizations, ED visits, and outpatient visits by under-5 child mortality rates of the country showed, in general, higher VE in countries with low under-5 mortality rates, and consistently lower VE in countries with high under-5 mortality rates (Figure 3 ). For RV1, median VE was 84% (range, 19%-97%) for 13 studies from low-mortality countries; 75% (range, -2% to 94%) for 8 studies from medium-mortality countries; and 57% (range, 18%-69%) for 9 studies from high-mortality countries ( Figure 4A ). In the same subsets of studies, VE from random-effects models was 82% (95% CI, 72%-88%), 66% (95% CI, 50%-77%), and 58% (95% CI, 51%-65%), respectively; however, the I 2 and Q statistics showed heterogeneity in the low-mortality (Q statistic = 117.9, P < .001; I 2 = 85.8%) and medium-mortality (Q statistic = 21.8, P = .003; Figure 5A ). For RV5, median VE was 90%
(range, 63%-100%) for 20 studies from low-mortality countries and 45% (range, 43%-92%) for 7 studies from high-mortality countries ( Figure 4B ). In the same subsets of studies, VE from random-effects models was 86% (95% CI, 82%-89%) and 58%
(95% CI, 39%-57%), respectively; however the I 2 and Q statistics showed heterogeneity in the low-mortality (Q statistic = 56.4, P < .001; I 2 = 52.0%) countries ( Figure 5B ).
Vaccine Effectiveness by Completeness of Vaccination Series
For 15 studies across mortality strata, point estimates of VE against rotavirus hospitalizations for a full series of vaccine were higher than those for a partial series, though these observed differences were not reported to be statistically significant in any of these studies (Table 1) . For 16 RV1 studies, the median difference in VE point estimates for 2 doses vs 1 dose of vaccine for the mortality strata low, medium, and high was -3%, 14%, and 17%, respectively. For RV5 studies, the median difference in VE point estimates was 7% when comparing 3 vs 2 doses and 16% when comparing 3 doses vs 1 dose for 5 studies from low-mortality countries. Only 1 study reported RV5 partial dose VE from a high-mortality country.
Vaccine Effectiveness by Age
RV1 point estimates of VE against rotavirus hospitalizations and ED visits were higher among children <12 months of age than children ≥12 months of age in 1 of the 4 studies from low-mortality countries, in all 6 studies from medium-mortality countries, and in 3 of 6 studies from high-mortality countries ( Table 2 ). The overall median percentage difference in VE point estimates between children <12 months of age and children ≥12 months of age was 8% (range, −30% to 164%); for low-, medium-, and high-mortality countries, the median differences were -5%, 31%, and -1%, respectively. RV5 VE point estimates were higher among children <12 months of age than those ≥12 months of age in 4 of 7 studies from low-mortality countries, and 2 of 3 studies from high-mortality countries (Table 2) . Overall, the median percentage difference was 4% (range, −16% to 34%). The median difference was 4% and 23% for low-mortality and high-mortality countries, respectively. These observed differences in VE point estimates were not statistically significant.
Vaccine Effectiveness by Rotavirus Disease Severity
Six studies from 2 low-mortality countries reported VE estimates against rotavirus hospitalizations and ED visits, of which 3 reported separate VE estimates for both RV1 and RV5 (Table 3 ). The median RV1 VE estimate against rotavirus hospitalizations and ED visits was 88% (range, 70%-95%) and 80%
(range, 78%-86%), respectively. The median RV5 VE estimates against rotavirus hospitalizations and ED visits was 94% (range, 83%-100%) and 81% (range, 74%-91%), respectively. The median VE point estimate percentage difference between hospitalizations and ED visits was 5% (range, -8% to 14%) and 9% (range, 5%-21%) for RV1 and RV5, respectively. Eleven studies from medium-and high-mortality countries provided estimates of VE against severe and very severe rotavirus gastroenteritis as defined by Vesikari scores of ≥11 and ≥15, respectively (Table 3 ). Of the 9 RV1 studies, the median VE point estimate for Vesikari score ≥11 was 54% (range, -54% to 73%) and for a score of ≥15 was 64% (range, -114% to 83%). For the 2 RV5 publications, the VE point estimates for Vesikari score ≥11 was 57% (range, 51%-63%); for Vesikari score of ≥15, the median VE point estimate was 72% (range, 58%-86%). The median percentage difference in VE point estimates between very severe and severe rotavirus gastroenteritis was 9% and 15% for RV1 and RV5, respectively. However, the observed VE differences were not statistically significant.
DISCUSSION
This comprehensive review of the first decade of postlicensure data on rotavirus VE from 24 countries in various geographic regions and with different child mortality levels demonstrates that, under routine use, both RV1 and RV5 are effective in preventing healthcare visits due to rotavirus infection in infants and young children. The gradient in vaccine efficacy that was observed between developed and developing countries in clinical trials was also seen in postlicensure studies, with lower VE in countries with a higher level of child mortality compared with countries with low child mortality [5] [6] [7] [8] [9] 57] . However, our data demonstrate that both vaccines are effective against rotavirus gastroenteritis across a range of mortality settings, thus providing additional support for the WHO recommendation that all countries introduce rotavirus vaccine into their national immunization program.
Because most children in prelicensure trials completed the full vaccination series, the information available on partial series protection was largely based on rotavirus cases that occurred during the interval between vaccine doses; thus, the longevity of protection from a partial vaccination series could not be examined. Our review of postlicensure data showed that a partial series of both RV1 and RV5 provided considerable protection against severe rotavirus disease through the first 2 years of life. This finding is encouraging given that in real-world vaccination programs, particularly in developing countries, many children may not complete their full vaccination series. However, in general, the effectiveness of a partial vaccination series was lower than that of a full series. Furthermore, because most studies assess VE only in children up to 2 years of age, the durability of protection from a partial series at older ages could not be assessed. Thus, all efforts should be made to ensure the children receive the full series to achieve optimum protection against rotavirus disease. Our review of postlicensure data reaffirms that both RV1 and RV5 maintain good effectiveness in routine programmatic use over the first 2 years of life in low-mortality countries [6, 57] . However, trials in developing countries of Asia and Africa suggested a decline in vaccine efficacy in the second year of life compared to the first year, although they were not statistically powered to make firm conclusions [7-9, 58, 59] . We found that RV1 effectiveness was lower in the second year of life compared with the first year of life in 9 of the 12 studies from developing countries with medium and high mortality, supporting evidence of waning effectiveness. However, 3 of the studies showed no decline in RV1 effectiveness in the second year of life. Thus, as additional evidence is gathered, particularly from countries with high child mortality, the possibility of waning in VE by age should be further examined.
Consistent with data from clinical trials and from studies assessing the protection conferred by natural rotavirus infection [7-9, 57, 58] , both RV1 and RV5 demonstrated greater effectiveness against rotavirus disease of greater severity: VE was greater against rotavirus hospitalizations compared with ED visits, and against very severe rotavirus disease compared to severe disease, based on the Vesikari scoring system. This finding is particularly encouraging regarding the potential benefits of vaccination in preventing mortality from very severe rotavirus disease, and indeed many countries have demonstrated sharp declines in diarrhea mortality after the routine implementation of rotavirus vaccines [31, 47, 48] . Our review has some limitations. While many of the VE evaluations were conducted using the approach described in a WHO generic protocol, some heterogeneity in study endpoints and designs requires caution in comparing data between studies [60] . For the meta-analysis, these data did not meet the assumptions for qualitative heterogeneity or the quantitative heterogeneity assessments. Additionally, some mortality strata had fewer than the recommended 10 articles contributing to the model. Many of the sample sizes were limited and statistically significant differences in VE between subgroups, such as by age and disease severity, were not detected. As with any review, there is the possibility of publication bias in our results; we followed the PRISMA guidelines [21] to assess for this and did not find evidence of publication bias. Also, we did not assess VE by specific strain type as this was examined in a separate review published recently [61] .
Our data demonstrate that both rotavirus vaccines are effective against rotavirus gastroenteritis across a range of mortality settings, providing additional support for the WHO recommendation that all countries introduce rotavirus vaccine into their national immunization program [10] . While these results are promising, further evaluation is needed of VE against less severe rotavirus disease and as vaccinated children age. In particular, data from Asia are sparse given the limited vaccine introduction in this region to date. Continuing to conduct VE evaluations in a variety of geographic settings across a range of mortality and different subpopulations will support efforts to evaluate and optimize rotavirus vaccine performance.
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